Login / Signup

De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.

Robert H GrossJohn Corboy
Published in: Current neurology and neuroscience reports (2024)
Observational and interventional studies have shed light on what happens to patients who de-escalate or discontinue DMTs and the factors, such as age, treatment type, and presence of recent disease activity, that influence outcomes. Though many questions remain, recent findings have been valuable for the development of an evidence-based approach to making de-escalation and discontinuation decisions in MS.
Keyphrases